Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 1
1979 2
1982 1
2013 1
2016 1
2017 3
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors.
Farrell PJ, Zopf CJ, Huang HJ, Balakrishna D, Holub C, Bilakovics J, Fanjul A, Matuszkiewicz J, Plonowski A, Rolzin P, Banerjee U, Ermolieff J, Cheruvallath ZS, McBride C, Bartkowski D, Mazur C, Pachori A, Larson CJ. Farrell PJ, et al. Among authors: matuszkiewicz j. J Pharmacol Exp Ther. 2019 Nov;371(2):299-308. doi: 10.1124/jpet.119.259028. Epub 2019 Sep 19. J Pharmacol Exp Ther. 2019. PMID: 31537613
Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.
Chen YK, Bonaldi T, Cuomo A, Del Rosario JR, Hosfield DJ, Kanouni T, Kao SC, Lai C, Lobo NA, Matuszkiewicz J, McGeehan A, O'Connell SM, Shi L, Stafford JA, Stansfield RK, Veal JM, Weiss MS, Yuen NY, Wallace MB. Chen YK, et al. Among authors: matuszkiewicz j. ACS Med Chem Lett. 2017 Jul 27;8(8):869-874. doi: 10.1021/acsmedchemlett.7b00220. eCollection 2017 Aug 10. ACS Med Chem Lett. 2017. PMID: 28835804 Free PMC article.
Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
Lam B, Arikawa Y, Cramlett J, Dong Q, de Jong R, Feher V, Grimshaw CE, Farrell PJ, Hoffman ID, Jennings A, Jones B, Matuszkiewicz J, Miura J, Miyake H, Natala SR, Shi L, Takahashi M, Taylor E, Wyrick C, Yano J, Zalevsky J, Nie Z. Lam B, et al. Among authors: matuszkiewicz j. Bioorg Med Chem Lett. 2016 Dec 15;26(24):5947-5950. doi: 10.1016/j.bmcl.2016.10.087. Epub 2016 Nov 2. Bioorg Med Chem Lett. 2016. PMID: 27839918
MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody.
Farrell PJ, Matuszkiewicz J, Balakrishna D, Pandya S, Hixon MS, Kamran R, Chu S, Lawson JD, Okada K, Hori A, Mizutani A, Iwata H, de Jong R, Hibner B, Vincent P. Farrell PJ, et al. Among authors: matuszkiewicz j. Mol Cancer Ther. 2017 Jul;16(7):1269-1278. doi: 10.1158/1535-7163.MCT-16-0771. Epub 2017 Mar 24. Mol Cancer Ther. 2017. PMID: 28341789
Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
Bennett MJ, Wu Y, Boloor A, Matuszkiewicz J, O'Connell SM, Shi L, Stansfield RK, Del Rosario JR, Veal JM, Hosfield DJ, Xu J, Kaldor SW, Stafford JA, Betancort JM. Bennett MJ, et al. Among authors: matuszkiewicz j. Bioorg Med Chem Lett. 2018 Jun 1;28(10):1811-1816. doi: 10.1016/j.bmcl.2018.04.016. Epub 2018 Apr 10. Bioorg Med Chem Lett. 2018. PMID: 29657099
Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.
Farrell P, Shi L, Matuszkiewicz J, Balakrishna D, Hoshino T, Zhang L, Elliott S, Fabrey R, Lee B, Halkowycz P, Sang B, Ishino S, Nomura T, Teratani M, Ohta Y, Grimshaw C, Paraselli B, Satou T, de Jong R. Farrell P, et al. Among authors: matuszkiewicz j. Mol Cancer Ther. 2013 Apr;12(4):460-70. doi: 10.1158/1535-7163.MCT-12-0657. Epub 2013 Jan 28. Mol Cancer Ther. 2013. PMID: 23358665
12 results